News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Oesophagus → cancer profile · × Clear filters
Alcohol-attributable cancer deaths in the USA doubled between 1990 and 2023
Cancer deaths attributable to alcohol in the USA rose from 11,361 in 1990 to 23,126 in 2023 — a doubling over 33 years. The figures come from a secondary analysis of Global Burden of Disease data, so they are attributable-fraction estimates rather than counted deaths: they describe the scale of the problem in a population, not the risk faced by any one person. Increases spanned liver, breast, colo…
'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer
On 25 August 2026 the FDA approved zanidatamab (Ziihera) in the first-line treatment of unresectable locally advanced or metastatic HER2-positive gastric, gastro-oesophageal junction and oesophageal adenocarcinoma. In the registration trial HERIZON-GEA-01 (NCT05152147) the zanidatamab plus tislelizumab regimen extended median overall survival to 26.4 versus 19.2 months (HR 0.72; 95% CI 0.57-0.90; …
Disitamab Vedotin, Tislelizumab, and S-1 as First-Line Treatment for Advanced Gastric Cancer
First-line disitamab vedotin plus tislelizumab and S-1 in HER2-overexpressing advanced gastric or gastro-oesophageal junction adenocarcinoma achieved an objective response rate of 89.5% (95% CI 78.5-96.0), but at a cost in toxicity: grade 3 or worse treatment-related adverse events occurred in 64.9% of patients. In this single-arm phase 2 trial (n=57, median follow-up 28.2 months), median progress…
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
In patients whose tumours expressed tsMHC-II, adding tislelizumab to perioperative chemotherapy raised the major pathological response rate from 26.5% to 61.8% (p=0.003), meeting the prespecified primary endpoint — but this is a phase 2 trial in 136 patients, and the endpoint measured response in the resected specimen, not survival. No benefit was seen in the tsMHC-II-negative subgroup. Within the…
Barrett’s Esophagus
The New England Journal of Medicine has published a comprehensive review article on Barrett's Esophagus, a well-established precancerous condition in which the normal squamous lining of the esophagus is replaced by specialized intestinal-type columnar epithelium. Barrett's Esophagus is the primary recognized precursor to esophageal adenocarcinoma, a cancer whose incidence has risen significantly i…
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
The American Society of Clinical Oncology (ASCO) has published an updated clinical practice guideline on immunotherapy and targeted therapy in advanced gastroesophageal cancer in the Journal of Clinical Oncology (April 2026). The update consolidates evidence from registrational trials and restates the recommended treatment sequences, biomarker-driven agent selection and combination regimens for pa…